Which has stronger valuation and earnings, DXCM or HAE?

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.82B 5.80 $836.30M $2.34 30.97 Haemonetics $1.33B 2.52 $97.31M $2.02 36.68

Is DXCM or HAE more profitable?

DexCom has a net margin of 19.31% compared to Haemonetics' net margin of 7.29%. DexCom's return on equity of 33.33% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Haemonetics 7.29% 27.30% 9.59%

Which has preferable valuation and earnings, HAE or LNTH?

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.52 $97.31M $2.02 36.68 Lantheus $1.54B 4.39 $233.56M $4.15 25.04

Is HAE or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Haemonetics' net margin of 7.29%. Lantheus' return on equity of 29.32% beat Haemonetics' return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Lantheus 18.05% 29.32% 15.00%

Which has higher earnings & valuation, HAE or PODD?

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.52 $97.31M $2.02 36.68 Insulet $2.71B 3.73 $247.10M $4.30 33.90

Is HAE or PODD more profitable?

Insulet has a net margin of 10.44% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Insulet 10.44% 26.87% 12.01%

Which has higher earnings & valuation, HAE or QTRX?

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.52 $97.31M $2.02 36.68 Quanterix $138.90M 1.15 -$107.15M -$2.36 N/A

Is HAE or QTRX more profitable?

Haemonetics has a net margin of 7.29% compared to Quanterix's net margin of -71.86%. Haemonetics' return on equity of 27.30% beat Quanterix's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Quanterix -71.86% -23.92% -17.66%

Haemonetics (HAE) Competitors

$74.10 +1.37 (+1.88%)

Closing price 03:59 PM Eastern

Extended Trading

$74.17 +0.07 (+0.09%)

As of 04:26 PM Eastern

Compare

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

Should you buy Haemonetics stock or one of its competitors? MarketBeat compares Haemonetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), and Quanterix (QTRX). These companies are all part of the "medical" sector.

How does Haemonetics compare to DexCom?

DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

DexCom has higher revenue and earnings than Haemonetics. DexCom is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.82B	5.80	$836.30M	$2.34	30.97
Haemonetics	$1.33B	2.52	$97.31M	$2.02	36.68

DexCom currently has a consensus target price of $84.83, suggesting a potential upside of 17.06%. Haemonetics has a consensus target price of $78.33, suggesting a potential upside of 5.71%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts clearly believe DexCom is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

DexCom has a net margin of 19.31% compared to Haemonetics' net margin of 7.29%. DexCom's return on equity of 33.33% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Haemonetics	7.29%	27.30%	9.59%

In the previous week, DexCom had 24 more articles in the media than Haemonetics. MarketBeat recorded 25 mentions for DexCom and 1 mentions for Haemonetics. DexCom's average media sentiment score of 1.14 beat Haemonetics' score of 0.00 indicating that DexCom is being referred to more favorably in the media.

Company	Overall Sentiment
DexCom	Positive
Haemonetics	Neutral

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DexCom has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

DexCom beats Haemonetics on 14 of the 17 factors compared between the two stocks.

How does Haemonetics compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

HealthEquity has higher earnings, but lower revenue than Haemonetics. HealthEquity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.42	$215.20M	$2.67	31.91
Haemonetics	$1.33B	2.52	$97.31M	$2.02	36.68

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.6% of HealthEquity shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HealthEquity has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

HealthEquity has a net margin of 17.25% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.25%	14.75%	9.22%
Haemonetics	7.29%	27.30%	9.59%

HealthEquity presently has a consensus price target of $110.57, suggesting a potential upside of 29.76%. Haemonetics has a consensus price target of $78.33, suggesting a potential upside of 5.71%. Given HealthEquity's stronger consensus rating and higher probable upside, equities analysts plainly believe HealthEquity is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, HealthEquity had 6 more articles in the media than Haemonetics. MarketBeat recorded 7 mentions for HealthEquity and 1 mentions for Haemonetics. HealthEquity's average media sentiment score of 1.33 beat Haemonetics' score of 0.00 indicating that HealthEquity is being referred to more favorably in the media.

Company	Overall Sentiment
HealthEquity	Positive
Haemonetics	Neutral

Summary

HealthEquity beats Haemonetics on 9 of the 16 factors compared between the two stocks.

How does Haemonetics compare to Lantheus?

Haemonetics (NYSE:HAE) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Lantheus has higher revenue and earnings than Haemonetics. Lantheus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.52	$97.31M	$2.02	36.68
Lantheus	$1.54B	4.39	$233.56M	$4.15	25.04

Lantheus has a net margin of 18.05% compared to Haemonetics' net margin of 7.29%. Lantheus' return on equity of 29.32% beat Haemonetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Lantheus	18.05%	29.32%	15.00%

In the previous week, Haemonetics and Haemonetics both had 1 articles in the media. Haemonetics' average media sentiment score of 0.00 equaled Lantheus'average media sentiment score.

Company	Overall Sentiment
Haemonetics	Neutral
Lantheus	Neutral

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Haemonetics presently has a consensus target price of $78.33, suggesting a potential upside of 5.71%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 1.98%. Given Haemonetics' higher possible upside, research analysts plainly believe Haemonetics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Lantheus beats Haemonetics on 9 of the 15 factors compared between the two stocks.

How does Haemonetics compare to Insulet?

Haemonetics (NYSE:HAE) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Haemonetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Haemonetics currently has a consensus price target of $78.33, indicating a potential upside of 5.71%. Insulet has a consensus price target of $240.78, indicating a potential upside of 65.19%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

Insulet has a net margin of 10.44% compared to Haemonetics' net margin of 7.29%. Haemonetics' return on equity of 27.30% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Insulet	10.44%	26.87%	12.01%

99.7% of Haemonetics shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Insulet had 9 more articles in the media than Haemonetics. MarketBeat recorded 10 mentions for Insulet and 1 mentions for Haemonetics. Insulet's average media sentiment score of 1.09 beat Haemonetics' score of 0.00 indicating that Insulet is being referred to more favorably in the news media.

Company	Overall Sentiment
Haemonetics	Neutral
Insulet	Positive

Insulet has higher revenue and earnings than Haemonetics. Insulet is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.52	$97.31M	$2.02	36.68
Insulet	$2.71B	3.73	$247.10M	$4.30	33.90

Summary

Insulet beats Haemonetics on 12 of the 17 factors compared between the two stocks.

How does Haemonetics compare to Quanterix?

Haemonetics (NYSE:HAE) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Haemonetics currently has a consensus price target of $78.33, indicating a potential upside of 5.71%. Quanterix has a consensus price target of $4.00, indicating a potential upside of 17.99%. Given Quanterix's higher possible upside, analysts plainly believe Quanterix is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 1.5% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Haemonetics has a net margin of 7.29% compared to Quanterix's net margin of -71.86%. Haemonetics' return on equity of 27.30% beat Quanterix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Quanterix	-71.86%	-23.92%	-17.66%

Haemonetics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, Quanterix had 1 more articles in the media than Haemonetics. MarketBeat recorded 2 mentions for Quanterix and 1 mentions for Haemonetics. Quanterix's average media sentiment score of 0.03 beat Haemonetics' score of 0.00 indicating that Quanterix is being referred to more favorably in the news media.

Company	Overall Sentiment
Haemonetics	Neutral
Quanterix	Neutral

Haemonetics has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.52	$97.31M	$2.02	36.68
Quanterix	$138.90M	1.15	-$107.15M	-$2.36	N/A

Summary

Haemonetics beats Quanterix on 13 of the 17 factors compared between the two stocks.

Get Haemonetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HAE vs. The Competition

Export

Metric	Haemonetics	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$3.37B	$8.19B	$6.40B	$23.18B
Dividend Yield	N/A	2.53%	2.67%	4.07%
P/E Ratio	36.68	15.57	24.51	31.62
Price / Sales	2.52	6.07	553.78	103.64
Price / Cash	9.82	17.04	43.94	24.31
Price / Book	4.32	3.28	10.70	4.68
Net Income	$97.31M	$224.06M	$3.57B	$1.08B
7 Day Performance	-7.32%	-2.99%	0.56%	-0.26%
1 Month Performance	29.41%	2.15%	3.57%	2.18%
1 Year Performance	5.87%	-0.06%	28.49%	24.66%

Haemonetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HAE Haemonetics	1.8127 of 5 stars	$74.10 +1.9%	$78.33 +5.7%	+5.5%	$3.37B	$1.33B	36.68	3,009	Analyst Forecast
DXCM DexCom	4.586 of 5 stars	$74.22 -1.5%	$84.83 +14.3%	-13.0%	$29.08B	$4.66B	31.72	11,000	Positive News Analyst Forecast Insider Trade
HQY HealthEquity	4.8026 of 5 stars	$86.97 -1.6%	$110.57 +27.1%	-13.7%	$7.39B	$1.31B	32.57	2,814
LNTH Lantheus	2.2648 of 5 stars	$104.67 +0.1%	$101.86 -2.7%	+32.4%	$6.80B	$1.54B	25.22	1,193
PODD Insulet	4.5503 of 5 stars	$148.14 -1.0%	$240.78 +62.5%	-52.8%	$10.37B	$2.71B	34.45	5,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HAE) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Summary

How does Haemonetics compare to HealthEquity?

Summary

How does Haemonetics compare to Lantheus?

Summary

How does Haemonetics compare to Insulet?

Summary

How does Haemonetics compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Competitors

HAE vs. DXCM, HQY, LNTH, PODD, and QTRX

How does Haemonetics compare to DexCom?

Which has stronger valuation and earnings, DXCM or HAE?

Do analysts recommend DXCM or HAE?

Is DXCM or HAE more profitable?

Does the media prefer DXCM or HAE?

Do insiders & institutionals hold more shares of DXCM or HAE?

Which has more risk and volatility, DXCM or HAE?

Summary

How does Haemonetics compare to HealthEquity?

Which has stronger earnings and valuation, HQY or HAE?

Do insiders and institutionals have more ownership in HQY or HAE?

Which has more risk and volatility, HQY or HAE?

Is HQY or HAE more profitable?

Do analysts rate HQY or HAE?

Does the media prefer HQY or HAE?

Summary

How does Haemonetics compare to Lantheus?

Which has preferable valuation and earnings, HAE or LNTH?

Is HAE or LNTH more profitable?

Does the media favor HAE or LNTH?

Do institutionals & insiders hold more shares of HAE or LNTH?

Which has more volatility and risk, HAE or LNTH?

Do analysts rate HAE or LNTH?

Summary

How does Haemonetics compare to Insulet?

Which has more risk and volatility, HAE or PODD?

Do analysts prefer HAE or PODD?

Is HAE or PODD more profitable?

Do insiders & institutionals believe in HAE or PODD?

Does the media favor HAE or PODD?

Which has higher earnings & valuation, HAE or PODD?

Summary

How does Haemonetics compare to Quanterix?

Do analysts prefer HAE or QTRX?

Do insiders & institutionals believe in HAE or QTRX?

Is HAE or QTRX more profitable?

Which has more risk and volatility, HAE or QTRX?

Does the media favor HAE or QTRX?

Which has higher earnings & valuation, HAE or QTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HAE vs. The Competition

Haemonetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools